- Home
- ABOS
as of 01-20-2026 10:03am EST
$1.85
$0.05
-2.63%
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 114.5M | IPO Year: | 2021 |
| Target Price: | $7.67 | AVG Volume (30 days): | 220.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $2.46 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ABOS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 12, 2026
Avg Cost/Share
$1.71
Shares
8,548
Total Value
$14,658.11
Owned After
83,800
SEC Form 4
OConnell Daniel Joseph
Sell
Chief Executive Officer
ABOS Jan 12, 2026
Avg Cost/Share
$1.73
Shares
5,388
Total Value
$9,306.69
Owned After
593,510
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 9, 2026
Avg Cost/Share
$1.76
Shares
5,200
Total Value
$9,169.16
Owned After
83,800
SEC Form 4
OConnell Daniel Joseph
Sell
Chief Executive Officer
ABOS Jan 9, 2026
Avg Cost/Share
$1.76
Shares
12,941
Total Value
$22,831.81
Owned After
593,510
SEC Form 4
Doherty James J.
Sell
President and CDO
ABOS Jan 8, 2026
Avg Cost/Share
$1.82
Shares
6,467
Total Value
$11,768.65
Owned After
54,033
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 8, 2026
Avg Cost/Share
$1.82
Shares
36,911
Total Value
$67,245.96
Owned After
83,800
Barton Russell
Sell
Chief Operating Officer
ABOS Jan 8, 2026
Avg Cost/Share
$1.86
Shares
3,530
Total Value
$6,561.56
Owned After
123,269
SEC Form 4
OConnell Daniel Joseph
Sell
Chief Executive Officer
ABOS Jan 8, 2026
Avg Cost/Share
$1.82
Shares
8,143
Total Value
$14,815.37
Owned After
593,510
SEC Form 4
Doherty James J.
Sell
President and CDO
ABOS Jan 7, 2026
Avg Cost/Share
$1.99
Shares
1,700
Total Value
$3,379.43
Owned After
54,033
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 12, 2026 | Sell | $1.71 | 8,548 | $14,658.11 | 83,800 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 12, 2026 | Sell | $1.73 | 5,388 | $9,306.69 | 593,510 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 9, 2026 | Sell | $1.76 | 5,200 | $9,169.16 | 83,800 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 9, 2026 | Sell | $1.76 | 12,941 | $22,831.81 | 593,510 | |
| Doherty James J. | ABOS | President and CDO | Jan 8, 2026 | Sell | $1.82 | 6,467 | $11,768.65 | 54,033 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 8, 2026 | Sell | $1.82 | 36,911 | $67,245.96 | 83,800 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 8, 2026 | Sell | $1.86 | 3,530 | $6,561.56 | 123,269 | |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 8, 2026 | Sell | $1.82 | 6,888 | $12,512.74 | 209,951 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 8, 2026 | Sell | $1.82 | 8,143 | $14,815.37 | 593,510 | |
| Doherty James J. | ABOS | President and CDO | Jan 7, 2026 | Sell | $1.99 | 1,700 | $3,379.43 | 54,033 |
Latest Acumen Pharmaceuticals Inc. News
ABOS Breaking Stock News: Dive into ABOS Ticker-Specific Updates for Smart Investing
Compare ABOS vs Leading Stocks
See how ABOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.